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CHARACTERIZING THE SYMMETRY OF AMYLOID BETA PROTEIN 
RETENTION IN ALZHEIMER’S DISEASE USING FLORBETAPIR POSITRON 
EMISSION TOMOGRAPHY - 
A STUDY USING DATA FROM THE ALZHEIMER’S DISEASE 
NEUROIMAGING INITIATIVE 
HOAN T. NGUYEN 
ABSTRACT 
Progression of Alzheimer’s disease has been associated with the 
deposition of aggregated amyloid beta (Aβ) protein in the brain. Though first 
described in post-mortal tissue, the development of Aβ specific tracers for 
positron emission tomography (PET) permits in-vivo mapping of its distribution in 
the brain. One of the well-known and early-developed tracers is the Pittsburgh 
Compound B (PiB) (Klunk et al., 2004). However, the challenge with PiB lies in 
the stability of the radioisotope 11C. 11C’s short half-life of only 20 minutes hinders 
its transportation and usage at imaging facilities that are not in close proximity 
with the radioisotopes manufacturer. Recently, an alternative Aβ tracer has been 
developed, Florbetapir (Wong et al, 2010.), with a half-life of 110 minutes that 
should allow wider accessibility to imaging sites while improve the detection of 
Aβ. To define better the specificity and utility of Florbetapir, we propose to utilize 
existing PET data acquired with the radioactive tracer Florbetapir from the 
Alzheimer’s disease Neuroimaging Initiative (ADNI). Our goal is to characterize 
the symmetry of Aβ protein deposition in the brain of patients with Alzheimer’s 
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disease. While a previous study has investigated this issue using PiB, Florbetapir 
has not been used. Our project will involve data post-processing by segmenting 
out non-brain tissues. Segmented data is then normalized by the pixel intensity 
and a distribution curve is created using MathCad program. In addition, we will 
calculate the asymmetry score for Regions of Interest. This will permit 
comparison of the uptakes of tracer between brain hemispheres to be made. 
Results from our project can provide insight into Florbetapir’s binding affinity for 
Aβ. In addition, Florbetapir’s potential as a better alternative to PiB can also be 
evaluated. 
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INTRODUCTION 
 
The purpose of this study is to develop a quantitative approach to analyze 
the diagnostic capability of the radioactive tracer Florbetapir 18F-AV-45 by 
studying the histograms generated for the whole brain and each hemisphere 
from PET data acquired using this tracer. The radioactive tracer AV45 has been 
developed recently and is widely studied due to its specific binding to beta-
amyloid plagues, a biomarker for Alzheimer’s disease. The data is taken from 
Alzheimer’s Disease Neuroimaging Initiative a foundation funded by the National 
Institute on Aging, in conjunction with other federal agencies and private-sector 
corporations and organizations.  ADNI is the NIH’s largest public-private 
partnership on brain research that tracks normal, mildly cognitively impaired 
(MCI), and Alzheimer’s disease brain changes to measure the progression of the 
condition. A total of 20 subjects with Alzheimer’s disease (AD) are studied using 
3DSlicer (version 2.6, bwh.harvard.edu) and ImageJ (wsr@nih.gov). Data was 
download from ADNI is converted to different formats and segmented to remove 
cranium from the brain itself. A MathCad script was developed by Dr. Jara 
(Boston Medical Center, hjara@bu.edu) to automatically segment out the  
cerebral spinal fluid and generates histograms for the whole brain and each 
hemisphere. By studying the histograms generated and its laterality score, 
information about the symmetry of beta-amyloid protein deposition in the brain 
can be evaluated.  
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A potential benefit to society that may be derived from this research is the 
use of histograms, along with other parameters to quantitatively assess PET 
results of patients in addition to Standard Uptake Value Ratios or SUVRs. A 
quantitative approach, rather than qualitative, can provide more reliable 
information. Another potential benefit coming from studying beta-amyloid protein 
is to help understand how their deposition plays a role in AD. 
Alzheimer’s disease is one of the leading causes of dementia, accounting 
for more than half of all cases in the United States (~70%) (Herbert et al., 2003). 
A recent study shows that the challenge in fighting the disease is that the clinical 
signs of dementia may appear as late as 20 years after the underlying pathology 
starts (Holtzman et al., 2011). This, however, means there is a possibility of 
detecting the disease when it is at its preclinical stage. If detection of AD can be 
done pre-clinically, new therapies can be developed to focus on the prevention or 
delay the onset of clinical signs and symptoms. Although, the exact cause of 
Alzheimer’s disease is still unknown, many biomarkers of the disease have been 
identified. Among these biomarkers, extracellular plaques composed of beta-
amyloid (Aβ) and intraneuronal neurofibrillary tangles (NFTs) composed of 
hyperphosphorylated tau have been widely studied (Mirra et al., 1991). According 
to the National Institute of Neurological and Communicative Disorders and Stroke 
and the Alzheimer’s Association, current criteria for diagnosis of possible or 
probable AD require the presence of cognitive impairment and suspected 
dementia syndrome, confirmed by neuropsychological testing. A definitive 
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diagnosis requires a histopathologic confirmation with brain tissue being 
examined under a microscope. Therefore, much needed first is the improvement 
in the diagnostic capability in order to fight the disease. 
Many advances in Positron Emission Tomography have opened up the 
possibility for a minimal invasive approach in detecting the biomarkers, 
specifically Aβ. The rationale is to develop a ligand, which is a molecule or a 
functional group that binds specifically to the biomarker of interest such as Aβ. 
And by making this ligand detectable, the target biomarker can be detected. To 
make the ligand detectable using PET, it is chemically incorporated to a 
radiopharmaceutical containing radioactive isotope with a relatively short half-life. 
When the radioactive isotope undergoes positive beta decay, it emits a positron, 
which is an anti-particle opposite to electron. The positron emitted travels in 
tissue for a few millimeters and loses its kinetic energy, slow down enough to 
interact with electron. The interaction is called annihilation and gives off two 
photons traveling in almost opposite directions. Detection of these photons gives 
signal in PET and allows the localization of the radioactive tracers in tissues to be 
known (Phelps, 2006). Many radioactive tracers designed to detect Aβ have 
been developed in recent years. Two of the well-known tracers which show 
promising potential due to their affinity to Aβ are Pittsburgh Compound B [11C] 
PIB and Florbetapir AV-45. However, the very short half-life of PiB (about 20 
minutes) makes it difficult for smaller research centers to acquire and use. AV45 
on the other hand has a half-life of 110 minutes. 
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Results from various studies (Lin et al., 2010 and Clark et al., 2011) shows that 
PET data acquired with AV-45 have potentially good diagnostic capability for AD. 
In Wong et al., 2010 article titled Vivo Imaging of Amyloid Deposition in 
Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18), AV 45 
PET was performed on 16 patients with AD and 16 health controls. Dynamic PET 
done resulted in data showing accumulations of AV45 in cortical regions 
expected to be high in Aβ in the AD group and minimal accumulation of AV45 in 
control group. The experiment concluded there is a significant difference 
between AD patients and HC based on calculated standardized uptake value 
ratio (SURV) and distribution volume ratio).  
The objective of this study is to generating histograms of the whole brain 
using data acquired from ADNI. Specifically, histograms generated from PET 
data done with AV45 radioactive tracer will be studied and compared to 
characterize beta-amyloid deposition. 
The hypothesis is that the histograms generated from PET data for the 
each brain hemisphere will show no significant difference the left and the right 
side group consistent with results done from previous study done using PiB (Raji 
et al., 2008) 
Limitations to the results of this study are the small population and the lack of 
more diverse groups of subjects, such as mild cognitive impairment, early stage 
Alzheimer’s disease or preclinical Alzheimer’s disease and other types of 
dementia patients. Diversity among subjects can provide more information to 
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better evaluate the radioactive tracer specificity when it binds to the biomarker 
beta-amyloid. In addition imaging protocols and image qualities are different for 
many sets of data due the fact that they are acquired at different search centers, 
no MRI data corresponding to the PET data for each subject also makes it 
difficult to identify structures and cortexes in the brain. 
Because this research is more of a technical project in which we develop 
algorithm to generate histograms for the whole brain and each of its 
hemispheres, the research design is simple. Group assignment is based on the 
patients’ diagnostic information in the database. There is only one AD group with 
no placebo group. Data of the patients are randomized selected from available 
data. 
In this experiment data is be segmented using a widely known software 
such as 3Dsclier, segmented data is then converted to .raw format, and ran 
through a histogram generating script using MathCad. The dependent factor here 
is the signal intensity. The experiment is applied by injection of the radioactive 
tracer AV45 into the subjects. Tissues in the body absorb the tracer at different 
concentrations. As the tracer decays, it emits particles called positrons. 
Annihilation of a positron and an electron creates a pair of photons traveling in 
proximately opposite directions. Detection of these pairs of photons gives the 
signal in PET. There are 20 subjects from AD group. Each is processed for three 
histograms, one for the whole brain and one for each hemisphere. 
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The reason for the sample size of 20 per group is the estimated Cohen d 
value of roughly 0.8. Therefore, with the sample size above, there is about 80% 
chance that a significant difference can be found from this study. In addition, 
because this sample size is what other similar studies have been using. 
The plan for data analysis including generating histograms for the whole brain 
and each hemisphere 
Parametric analysis: 
Cochran test to determine if two samples the left and right hemisphere are of 
equal or unequal variances.  
Based on the Cochran test result, t-test of two sample assuming equal or 
unequal variances will be used. 
If data for another radioactive tracer was to be analyzed, multifactor 
Analysis of Variance (multifactor ANOVA) would have been used with possible 
priori test for post-ANOVA follow up comparison using contrast analysis. 
All of the analyses help determine if there is a significant difference between the 
groups and whether that difference due to chance. 
The pitfall of this study is that it works on the assumption that Aβ plaques 
accumulations indicate probable AD. However, Aβ itself is not the cause of Aβ 
and it has been shown have other functions in the body. It is not possible to work 
around this issue until more information about the exact cause of AD can be 
understood. 
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A brief history of PET imaging 
 Positron Emission Tomography has been used extensively for the purpose 
of tracking and diagnosing tumors in the body. The developments of the positron 
imaging spans many years of research and includes contributions from many 
individuals. Perhaps, one if the most well-known person whose name is 
associated with the introduction of PET into medical imaging is Dr. Gordon 
Brownell (MGH, MIT). During 1950s when imaging tumor often poses challenges, 
Brownell suggested annihilation radiation and position imaging be used to 
enhance the quality of imaging, especially in the brain. The idea was quickly 
applied and in 1951, imaging of patients with brain tumor using position was 
commenced at Massachusetts General Hospital. Following the successful 
prototypical instrument, the first clinical position imaging scanner was built in 
1961. In addition to producing coincidence scan; the device also produced what 
was called unbalance scan with sensitivity to tumor location (Brownell, 1999). 
 
Figure 1: Scans created from the first positron imaging device. 
Coincidence and unbalance scans of patient with recurring brain tumor. 
7 
 
Coincidence scan (a) showing reoccurrence of tumor under previous 
operation site and unbalance scan (b) showing asymmetry to the left. 
By the mid-1960s, the demand for a device with increased sensitivity to tumor 
accelerated the development of multi-detector scanner. Not only using multiple 
row of detectors, the scanner could also produce 3D images allowing clinicians to 
evaluate the tumor location in two dimensions. The first computed tomographic 
imaging device was completed in 1969 called PC-I and PC-II incorporated filter 
back projection developed by David Chester in 1970 at MGH (Chester, 1971). 
 
Figure 2: A commercial version of PC-II; the Cyclotron Corporation 
Positron Camera Version 4200 
 
At the very beginning of PET, early pharmaceutical used was mostly 15O labeled 
to O2, CO and CO2. This is because the first cyclotrons at MGH and Washington 
University were deuteron and used to produce 15O. 15O radioisotope remained 
8 
 
popular until the mid-1970s when more powerful cyclotrons became available 
and more radioisotopes such as 11C, 13N and 18F. It was worth to note that PET 
imaging became widely recognized and utilized in medicine due to the 
introduction of 18F (Brownell, 1999) 
Radiopharmaceuticals 
Radiopharmaceuticals are materials that incorporate a radioactive tracer 
(substance containing a radionuclides) atom into a larger pharmaceutically-active 
molecule. Radionuclides, also known as radioisotopes are atoms with unstable 
nucleus which undergo radioactive decay. A few popular radioisotopes with their 
respective half-lives currently used in PET are: Flourine-18 (~110 minutes) most 
commonly seen in Fluorodeoxyglucose (FDG), Carbon-11 (~20 minutes) seen in 
PiB, Technetium-99m (~6 hours), Iodine-123 (~13.22 hours), Iodine-124 (4.2 
days) and Iodine-125 (59 days) (Nara et al., 1992). When incorporated into a 
substance that is normally metabolized by the body such as glucose and water, 
the radiation from the radioisotope allows that substance to be tracked. Different 
radiopharmaceutical can be taken up differently in the body. Different organs and 
tissues also metabolize the same radiopharmaceutical differently. The idea of 
using radioactive labeled radiopharmaceuticals to track their metabolism by the 
body traced back to George de Hevesy who received 1943 Nobel in Chemistry. 
In order for a substance to be used as radiopharmaceutical, it has to satisfy 
certain criteria: produce little or no physiological or pharmacological effects to 
ensure safety; no documented adverse reactions of clinical significance in many 
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studies and clinical trials on human; radiation exposure from a PET imaging 
procedure is comparable to that of other Nuclear Medicine diagnostic procedures 
using gamma-emitting radiopharmaceuticals; the radioactive substance used to 
evaluate the metabolic or physiologic process must not alter the process it is 
attempting to measure.  
Because of the instability of the radionuclides and their spontaneous decay, 
radiopharmaceuticals are typically produced in close proximity with the scanning 
site to ensure delivery time. Artificial production of radionuclides happens in 
several way: using nuclear reactor to create nuclide bombardment with neutrons, 
by-products from nuclear reactors in the process of nuclear fission or nuclide 
bombardment with other particles such as deuteron using particle accelerator 
(Jara, BMC). Particle accelerator called cyclotron is the dominant method to 
produce radionuclides used in PET. The pharmaceutical discussed in this paper 
is called Florbetapir also known as AV45.  
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Figure 3: Schematic of synthesis of Florbetapir (Yu, 2006) 
PET limitations 
One known problem with Positron Emission Tomography (PET) is 
determining accurately the localization of the pathology. The low resolution 
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makes it challenging to visualize the anatomy. To overcome this problem, 
Computed Tomography (CT) and PET are carried out in sequence. By fusing CT 
results in junction with PET, the high spatial resolution of anatomy in CT makes 
up for the low resolution in PET. This necessitates the need for sophisticated 
algorithm and software to provide fusion of CT and PET images. However, the 
process of alignment and co-registration is “labor-intensive” and almost 
impossible to be done perfectly due to body voluntary and involuntary 
movements. In addition, the positions of the patient at two different scanning 
occasions will always be vary. In other words, the approach of combining, 
correcting, co-registering and fusing CT and PET using software only will always 
have a limitation. This is where a hardware solution is needed. And the combined 
PET/CT is a promising solution to provide medical images with accurate 
anatomic information and functional information. A single scanning session 
where both PET and CT imaging can be done is not only more convenient for 
clinicians and patients but also minimizes patient movements, especially 
involuntary organ motions. In addition, alignment of the images will not be an 
issue since patient is only scanned one time.  
According to the authors, since CT was introduced in the early 1970s, it has 
become an important clinical tool due to its ability to perform “fast, reliable, high-
resolution and good quality” anatomic details. PET meanwhile was mainly used 
in neuroscience research rather than clinical until 1999 because of its low 
resolution, high signal noise and longer scan time. The two imaging modalities 
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are “complimentary” to each other. So the prototype for a hybrid PET/CT was 
manufactured by Siemens Medical Solutions in 1998. The prototype was a 
modified CT scanner with added PET capability. Separate consoles were used 
for each modality. The clinical results from scanning over 300 cancer patients 
sparked interest in major vendors. A new designed was created from CPS 
Innovations with less hardware integration and more of software integration. 
Unlike the first prototype, this design placed two separate scanners next to one 
another with a single control console. The software offers better image analysis 
tools for clinician in both imaging modalities, better fusion and image 
manipulation. Thus this design is what PET/CT scanners are using today. 
The first commercially marketed and approved by the FDA appeared in October 
2000 by Siemens Medical Solutions with GE Medical System had theirs 
marketed two months later, according to the authors. qAs the technology is 
becoming more available, more studies have been using data acquired from 
these hybrid systems. 
The authors point out one of the major advantages of the combined PET/CT is 
that PET transmission scanning session can be eliminated. Instead, CT scan is 
used to calculate PET attenuation correction factors (ACFs), free up to 40% 
scan-time and reduce noise in PET result. Mismatch between CT and PET 
images caused by patient breath can have serious effects. Approximately 2% in 
300 patients studied showed “lesions localized in the lung due to respiratory 
motion”. More research on protocols for patients breathing during CT and PET 
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scanning is being done. Another problem is the use of oral contrast can 
compromise the ACFs calculation and generate artifacts. 
Rotating LSO panel detectors are being developed for PET scanner help to 
reduce the number of bed positions and shorter imaging time for patients. New 
designs, scintillation materials, detector concepts and electronics are improving 
every day according to the authors. These improvements have already resulted 
in significantly reduced scan-time. Consequently, short scan-time reduces patient 
movements and cost-effective for clinical settings. Moreover, the authors noted 
there is also a demand for scanners with lesser performance in order to save 
cost of PET/CT scans. 
The combination of the two imaging modalities offers both functional and 
anatomical information in a single scanning session and eliminates many 
practical problems with traditional sequential scanning of each modality. Not only 
being more convenient for physicians and patients, it also reduces the possibility 
of misreading information due to technical error during co-registration, alignment 
and disease changes during the gap-time between CT scanning and PET 
scanning. Although more studies will be needed to further establish the 
technology use in patient care, the advantage of hybrid system like PET/CT is 
“indisputable” according to the authors. 
 
Radiation Safety 
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Although the risk from radiation in diagnostic imaging is minimal, 
nevertheless the risk is there. The dose delivered to patients are often measured 
or calculated. This brings the Absorbed dose: “the energy absorbed (from ejected 
electrons as they excite and ionize other atoms in their path) per unit mass of 
tissue” (J/kg). Absorbed dose is used for assessing both deterministic and 
stochastic risk to the skin for individual organs. 
Effective dose: is not a measured dose but rather a weighted sum of 
absorbed organ doses  
E = wT1D1 + wT1DT2 +…  
where w is the tissue weighted factor, T is the tissue sensitivity & D is the 
absorbed dosed for each tissue/organ. E is used to assess total stochastic risk 
relative to background radiation when multiple organs are involved & for general 
radiation protection purposes, somewhat similar to overall dose index. 
 Deterministic radiation risks: are risks from radiation in which there is a 
dose threshold. Below the dose threshold, no effect is observed. The severity of 
damages caused by deterministic radiation risks increases with increasing 
radiation dose. 
E.g. patient can develop transient erythema post Percutaneous Transluminal 
Coronary Angioplasty (PTCA) procedure. Erythema has a threshold of ~2 Gy 
(FDA publication) 
 Stochastic radiation risks: are risks from radiation with no dose threshold 
below which the risk is zero. The probability of the effect occurring increases with 
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increasing dose, but the severity of the effect is dose independent. These are: 
hereditary effects, carcinogenesis, and risks to embryo/fetus. 
E.g. Radiation induced breast cancer to women in the 1950s-60s 
Radiation induced cancer in atomic bomb survivors. 
 
Major radiation risks to the embryo/fetus from radiation: 
- Prenatal Death: in animal data, most sensitive 0-9 days post conception 
with threshold dose of 50-100 mGy, Human data is limited to high dose > 1 Gy. 
In survived embryos, few abnormalities are observed.  Atomic bomb data 
showed fewer baby born when irradiation happened earlier than 4 weeks old 
- Malformations resulted from radiation although rare, pose an increased 
risk for people with genetic predisposition 
- Structural malformations, low birth weight, neonatal death: most sensitive 
during organogenesis 10 days to-6 weeks post conception 
- Non-recoverable Growth Retardation: most sensitive during 10-56 days 
post conception 
- Small Head Size: most sensitive during 14-105 days post conception and 
not seen beyond 16 weeks. It is the most observed defect in atomic bomb 
survivor data. This defect is not associated with mental retardation and may not 
be caused by radiation alone 
- Mental Retardation: most sensitive 56-105 days post conception with 
neuronal development & migration of cerebral cortex. Possible threshold of ~100 
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mGy with 500 mGy being the threshold for the less sensitive period 112-175 
days 
- Intellectual deficit: 56-105 days post conception with no adverse effect 
when irradiation happened prior to 8 weeks, after 25 weeks or below 100 mGy 
- Seizures: 56-105 days, high prevalence to mental retardation, 100 mGy 
threshold 
- Childhood Cancer: problems in assessing the risk due to many factors 
such as background cancer rate, environmental effects & genetic makeup 
Perhaps best summarized in 
 
Figure 4: L. Wagner et al, Exposure of the Pregnant Patient to Diagnostic 
Radiations, 2nd Ed, 1997 
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Alzheimer’s Disease clinical diagnosis guidelines 
Clinical diagnosis guidelines for Alzheimer’s disease were proposed in 1984 and 
was updated for the very first time in 2011. 
Below is a short summary contrast between the two guidelines 
1984 
Addressed only one stage of disease—the final stage of dementia, which is when 
memory loss occurs and a decline in thinking abilities is severe enough to affect 
daily life. 
Memory loss as the first or only major symptom. 
Memory loss as the central emerging characteristic of Alzheimer’s dementia. 
Distinctions and associations between Alzheimer’s and non-Alzheimer’s 
dementias, as well as between Alzheimer’s and disorders that may influence its 
development, such as vascular disease were not well recognized or understood 
at the time (1984). 
Existence of biomarkers were not known, confirmation of the diagnosis was 
possible only through autopsy after death.  
Based chiefly on a doctor’s clinical judgment about the cause of a patient’s 
symptoms, taking into account reports from the patient, family members and 
friends, results of cognitive testing, and general neurological assessment. 
2011 
Identify three stages of the disease: 
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1. Preclinical: before symptoms such as memory loss occur and before one’s ability 
to carry out everyday activities are affected. 
2. MCI: is marked by symptoms of memory problems, enough to be noticed and 
measured, but not compromising a person’s independence. 
3. AD dementia: a decline in other aspects of cognition, such as word-finding, 
vision/spatial issues, and impaired reasoning or judgment may be the first 
symptom to be noticed 
Distinctions between Alzheimer’s dementia from other dementias can be aided 
with the results from tests for biomarkers  
Biomarker tests that measure biological changes in the brain associated with 
Alzheimer’s are incorporated. 
Biomarkers include elevated levels of tau or decreased levels of beta-amyloid in 
the CSF, reduced glucose uptake in the brain as determined by PET, and 
atrophy of certain areas of the brain as seen with structural magnetic resonance 
imaging (MRI) 
METHODS 
Review of ADNI acquisition protocol 
ADNI guidelines on data acquisition were established for research centers with 
regard to PET imaging. 
Image acquisition and techniques 
All PET scans are acquired using one of three different protocols: 
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1. Dynamic: a 30 minute, six frame acquisition (6 five-minute frames), with scanning 
from 30 to 60 min post-FDG injection; 
2. Static: a single-frame 30 min acquisition with scanning 30-60 min post-injection 
(for Siemens PET/CT scanners that do not have dynamic scan acquisition 
capability) 
3. Quantitative: a 60 min dynamic protocol consisting of 33 frames, with scanning 
beginning at injection and continuing for 60 min that can be used to compute 
absolute glucose metabolic rate from a calculated from radioisotope input 
function measured in the carotid arteries. The majority of the scans in the ADNI 
study were acquired with the first acquisition protocol. 
Raw data are in multiple different file formats, including DICOM, eCAT, matrix file 
format (CTI-7) and Interfile format. Here DICOM format was used. 
AV45 protocols 
Standard 4 x 300 sec frame dynamic PIB acquisition 
15 + 1.5 mCi (555 MBq) of AV45 Inject over 10-20 seconds 
Allow 40 minutes for the incorporation of AV45 into the brain. 
 
Acquire a dynamic, 3D scan consisting of 4 - 300 sec frames beginning 
approximately 50 minutes after tracer injection. 
All images will need to be corrected using measured attenuation. 
- PET Only Scanners 
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Acquire an attenuation correction scan using rod sources for 5-6 minutes after 
the acquisition of the emission scan. 
Segmentation and re-projection routines will be applied for attenuation correction. 
- PET/CT Scanners 
Standard CT acquisition parameters 
AD Group (n=24) 
Entering subjects with no previous FDG PET will be scanned at 0, 12, 24 months 
Subjects with baseline and 6 month FDG PET will be scanned at 12 and 24 
months 
1. Co-registered Dynamic 
Raw PET images from all sites are downloaded for quality control at University of 
Michigan. Raw images are converted to a standard file format. Separate frames 
are extracted from the image file for registration purposes. In most cases, six (6) 
five-minute frames are acquired 30 to 60 minutes post-injection. Each extracted 
frame is co-registered to the first extracted frame of the raw image file (frame 
acquired at 30-35 min post-injection). The base frame image and the five co-
registered frames (or all co-registered frames for the quantitative studies) are 
recombined into a co-registered dynamic image set. These image sets have the 
same image size (for example, 128×128×63) and voxel dimensions (for example, 
2.0×2.0×2.0 mm) and remain in the same spatial orientation as the original PET 
image data. This is called ‘native’ space. These files are uploaded to LONI in 
DICOM format. Only PET scans acquired under protocol 1 or 3 above, will have 
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a processed image set of this type. To summarize, PET image sets with a series 
description of “co-registered dynamic” have two primary differences from the 
“original” raw PET image data: 1) separate frames have been co-registered to 
one another lessening the effects of patient motion, and 2) image files are in 
DICOM format. 
2. Co-registered, Averaged 
This type of processed image set is generated simply by averaging the 6 five-
minute frames (or the last 6 frames for the quantitative studies) of the “Co-
registered Dynamic” image set described above. This creates a single 30 min 
PET image set still in “native” space. As above, only PET scans acquired under 
protocol 1 or 3 above, will have an entry of this type. 
3. Co-reg, Avg, Standardized Image and Voxel Size 
Each subject’s co-registered, averaged image from their baseline PET scan is 
then reoriented into a standard 160×160×96 voxel image grid, having 1.5 mm 
cubic voxels. This image grid is oriented such that the anterior-posterior axis of 
the subject is parallel to the AC-PC line. This is referred to as “AC-PC” space in 
the LONI search program. This standardized image then serves as a reference 
image for all PET scans on that subject. The individual frames from each PET 
scan (the baseline study as well as all subsequent studies (6-month scan, 12-
month scan, etc.) are co-registered to this baseline reference image. By doing 
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the co-registration from the original raw image data to a standardized space in a 
single step, only one interpolation of the image data is required, and thus 
resolution degradation by interpolation is kept to a minimum, and is the same for 
all scans. An averaged image is generated from the “AC-PC” co-registered 
frames and then intensity normalized using a subject-specific mask so that the 
average of voxels within the mask is exactly one. Both the spatial orientation 
(AC-PC) and the intensity normalization of the image are intended as a starting 
point for subsequent analyses. With a standardized image matrix, PET data from 
different scanner models can be compared more easily. It should be noted that in 
these images sets only spatial re-orientation and intensity normalization of scans 
has occurred. No non-linear warping or even linear scaling of the brain 
dimensions has been applied to the images. 
4. Co-reg, Avg, Std Img and Vox Siz, Uniform Resolution 
These images are the result of smoothing of the above-mentioned images. Each 
image set is filtered with a scanner-specific filter function (can be a non-isotropic 
filter) to produce images of a uniform isotropic resolution of 8 mm FWHM, the 
approximate resolution of the lowest resolution scanners used in ADNI. Image 
sets from higher resolution scanners obviously have been smoothed more then 
image sets from lower resolution scanners. The specific filter functions were 
determined from the Hoffman phantom PET scans that were acquired during the 
certification process. 
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Post processing 
Data are downloaded from ADNI database (www.adni-info.org) in DICOM 
(Digital Imaging and Communications in Medicine) format for each of the twenty 
subjects. Subjects selection is done by choosing search criteria including: 
diagnosis (AD), imaging modalities (PET) and tracer used (AV45). Each subject 
folder contains 96 DICOM files corresponding to 96 slices of the brain of each 
subject. These DICOM files are loaded as Image Sequence into ImageJ 
(Rasband, NIH) which enables information such as voxel size, slice thickness, 
pixel spacing and the matrix size to be obtained. This information is used to 
adjust parameters into Slicer (BWH) and MathCAD during the manual 
segmentation process and the generation of histogram based on signal intensity 
respectively. Using imageJ, DICOM files are converted into raw format saved as 
image sequence, with “IM” in file name follow by four digits in ascending order. 
Raw files are subsequently opened in Slicer 2.6 with appropriate parameters. 
Images are then stripped of non-brain matter (the skull) and saved as header 
less file format named seg follow by 4 digits in ascending order. These 
headerless files are finally placed in the same folder with the MathCAD script 
with name and parameters adjusted accordingly. Script is run twice once for each 
hemisphere of the brain. Two histograms, peak values, range, intra cranial 
volumes and head volumes are recorded for the left and right side of the brain for 
each subject. 
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RESULTS 
 
Right 
side 
Head 
Volume 
Right 
ICM 
Volume 
Right 
ICM/Right 
side 
Head 
Volume 
ratio 
Left 
side 
Head 
Volume 
Left  
ICM 
Volume 
Left 
ICM/Left 
side 
Head 
Volume 
ratio 
  722.6 606.8 84.0% 714.0 611.2 85.6% 
647.0 572.7 88.5% 606.3 534.1 88.1% 
684.7 576.3 84.2% 680.6 578.3 85.0% 
703.8 568.1 80.7% 700.8 685.8 97.9% 
618.8 564.3 91.2% 621.2 565.9 91.1% 
692.2 609.8 88.1% 690.3 600.6 87.0% 
690.5 600.6 87.0% 684.3 553.2 80.8% 
684.7 598.8 87.5% 689.7 590.2 85.6% 
604.9 525.8 86.9% 730.8 656.8 89.9% 
718.6 640 89.1% 714.6 658.2 92.1% 
648.6 586.7 90.5% 624.8 545.9 87.4% 
806.1 726.1 90.1% 801.4 677.7 84.6% 
670.7 598.4 89.2% 657.8 581.9 88.5% 
951.6 786.8 82.7% 948.5 740.5 78.1% 
798.7 700.2 87.7% 750.6 662.7 88.3% 
717.0 641.9 89.5% 689.4 616.1 89.4% 
714.6 685.4 95.9% 689.7 581.4 84.3% 
640.4 576.3 90.0% 651.1 580.1 89.1% 
845.0 756.2 89.5% 840.8 768.1 91.4% 
Table 1: Volume in cubic cm of the Right side of the head, right side 
intracranial matter, and Right side intracranial matter to head ratio of the 
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right side, volume in cubic cm of the Left side of the head, Left side 
intracranial matter and left side intracranial matter to head ratio 
 
Subject # Right Peak Min RU Max RU Range (Max- Min) 
1 2140 231 1005 774 
2 2271 213 1005 792 
3 3642 189 1005 816 
4 3229 213 1005 792 
5 3014 214 1005 791 
6 3015 225 1011 786 
7 2688 195 1023 828 
8 2352 189 1005 816 
9 2436 186 1005 819 
10 2776 213 1023 810 
11 3272 242 1023 781 
12 2483 243 1023 780 
13 3445 237 1005 768 
14 2527 225 1023 798 
15 3277 219 1023 804 
16 2478 207 1023 816 
17 2475 219 1023 804 
18 2737 201 1023 822 
19 2205 231 1023 792 
20 3170 225 1023 798 
     
Table 2: Histogram parameters for the right side 
Subject # Left Peak Min RU Max RU Range (Max- Min) 
1 2532 231 1023 792 
2 2283 213 1005 792 
3 3642 183 1005 822 
4 3229 225 1005 780 
5 3128 263 1005 742 
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6 2945 213 1005 792 
7 2730 177 1023 846 
8 2394 207 1023 816 
9 2254 204 1005 801 
10 2856 231 1023 792 
11 3189 243 1023 780 
12 2587 219 1023 804 
13 3173 243 1023 780 
14 2161 225 1023 798 
15 3140 243 1023 780 
16 2510 213 1023 810 
17 2537 213 1023 810 
18 2752 201 1023 822 
19 2348 213 1023 810 
20 3189 231 1023 792 
Table 3: Histogram parameters for the left side 
 
Figure 5: Histogram for subject 1 Right side of the brain 
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 Figure 6: Histogram for subject 1 left side of the brain 
 
Figure 7: Comparison chart for peak values between two hemispheres for 
each of the twenty subjects 
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Statistical Analysis 
t-Test: Two-Sample Assuming Equal 
Variances 
  
   
  
Range R (Max- 
Min) 
Range L (Max- 
Min) 
Mean 799.35 798.05 
Variance 287.2921053 466.7868421 
Observations 20 20 
Pooled Variance 377.0394737 
 Hypothesized Mean Difference 0 
 df 38 
 t Stat 0.211714178 
 P(T<=t) one-tail 0.416730735 
 t Critical one-tail 1.68595446 
 P(T<=t) two-tail 0.833461469 
 t Critical two-tail 2.024394164   
Figure 8: t-test analysis for the range between left and right side ot the 
brain 
 
t-Test: Two-Sample Assuming Unequal 
Variances 
  
     PeakL PeakR 
Mean 2781.6 2778.95 
Variance 199240.8 168094.3 
Observations 20 20 
Hypothesized Mean Difference 0 
 df 38 
 t Stat 0.019554 
 P(T<=t) one-tail 0.492251 
 t Critical one-tail 1.685954 
 P(T<=t) two-tail 0.984502 
 t Critical two-tail 2.024394   
Figure 9: t-test analysis for the peak values of the left and right side of the 
brain 
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DISCUSSION 
 
Following previous studies indicating AV-45 retention in the brain (Choi et 
al, 2009 and Wong et al, 2010), this project examines the symmetry in 
distribution of the tracer throughout the brain. The result data show that the 
degree of AV45 retention in the left side and right side of the brain is 
symmetrical. The result is as expected and In supporting the conclusion from a 
study in which PiB was used to characterize the retention of amyloid beta in 
Alzhiemer’s disease (Raji, 2008). The t-tests assuming equal variances, done on 
different parameters obtained from data analysis, give the p-values greater than 
0.05 (for the range values p= 83 and for the peak values, p=0.98). This indicates 
that the retention of tracer in the two sides of the brain is statistically the same. 
Graphical comparison based on forty histograms generated, two for each subject 
also shows similar results. The histograms for the other 19 subjects will be 
submitted as an attachment in Microsoft Excel file format. Limitations of this 
project are the small number of subjects and the lack of raw and clinical data 
from subjects who have undergone scanning. These limitations are due lack of 
resources to carry out a clinical research study. Due to these limitations, the 
analysis as to how the distribution of tracer in each hemisphere has to be done 
with alternative methods. In a pilot study using PiB (Raji et al, 2008) calculated 
Laterality score using formula LS = (Left ROI SUV – Right ROI SUV) / (Left ROI 
SUV + Right ROI SUV) where SUV is the Standard Uptake Value of Region Of 
Interest. SUV is proportional to the subject’s weight, which is unavailable for this 
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project. Therefore, alternative method of using histogram for graphical 
comparison and other parameters are employed. To my knowledge, there is no 
other study that provides a brain segmentation method to analyze ADNI post-
process PET imaging data, especially working with the absence of clinical data. 
The goal of this project is thus to provide additional methods to analyze these 
data in hope to gain useful information in addition to the information obtained 
conventionally such as SUV ratio. 
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